Researchers Explore Fetal CRISPR Gene Editing to Prevent Rare Genetic Diseases
Scientists are making significant strides in fetal gene editing, utilizing CRISPR technology to target rare genetic disorders before birth. Recent research led by experts at the University of Pennsylvania and the Children's Hospital of Philadelphia suggests that gene-editing tools can more easily reach vital organs like the heart and muscles in utero than after birth, when physiological barriers emerge. This breakthrough could potentially allow for the treatment of conditions such as Duchenne muscular dystrophy before irreversible damage occurs. While animal studies have shown promise, researchers caution that human clinical trials are likely at least three years away. The current focus remains on somatic cell editing to avoid the ethical controversies associated with germline (reproductive) cell modification.
Topics: CRISPR Fetal Gene Editing Genetic Diseases Medical Research